Easyonlinepaydayloan

CytoGenix Inc.

Slayer said: "Anybody have an opinion on this stock? The symbol is CYGX. It is currently trading at $.49 /share. Their website is [url]http://www.cytogenix.com/[/url] One of their drugs are coming to the market and has been approved by the FDA."

HappyHarry said: "When is the product coming to market?"

LanceJ said: "First thing I don't like about them is their filing of form NT-10Q on August 1st, 2005. They filed this 4 weeks after the reporting period ending June 30, 2005. Their reason to the SEC for failing to report in a timely manner was: "The Registrant is unable to file its 10-Q for period ended June 30, 2005 in a timely manner because the Registrant was not able to complete its financial statements without unreasonable effort or expense." It's just a sort of surreal situation where a company has the time and expense to release PR statements in a timely manner with the intent of pushing their stock upwards, but when it comes to actually reporting the facts of their operations, well, that somehow takes 2nd seat as an expenditure by the company as well as putting aside the time necessary to complete the filing. I punish companies brutally for failing to file on time with the SEC because over time, I've found it speaks to the competence of the people whose responsibility it is to get those statements out on time. I mean you can be delisted from the OTCBB for failing to file your 10Q. What is really more important than making sure this doesn't happen? Secondly, if I was holding this company, and they promised great things in their PR, I wouldn't want to sit around and wait 2 months and stress if they were going to file a 10Q statement at all and get bounced down to the pink sheets. But enough of that, I've toasted them enough. I'd watch this though in the future, and if they make a habit of filing late quarter after quarter, for this reason alone I'd take my investment dollars elsewhere. I'm going through their financial statements, will give you an opinion later."

LanceJ said: "First off, when going through the companies books, I see a very clear identification that the company is a "DEVELOPMENT STAGE COMPANY". Development stage company investing is an entire universe and speciality onto itself. I don't engage in development state company investing. The reason is that many more development stage companies fail than succeed. That's not to say I'm adverse to taking risk, on the contrar. But more to say that the risk associated with investing in a company like this exceeds even one of our pink sheet holdings, PLNI.PK. Pink sheets have no reporting requirements whatsoever and so fraud is much more abundant with securities listed there. However, Plasticon has a product, you know what the product is, and how they are trying to sell it. The idea being, you have a product to guage against demand. In a development stage company, they have no product, they are "developing" it. This adds an additional element of risk which we'll discuss below in a moment. There is, however, a way I would play a company like this. I would wait until their product is completed/if completed, and the company/if the company, moves out of the development stage process. There's plenty of time. You'll see an energy begin to build in the PRs and the quarterly filings. You'll see a PR about how Bristol Meyers will distribute XXXXXXX of the product. The volume will begin to build. The price will go into a long upward trend. You will see the company, as their revenues increase from sales, doing things like announcing a share buyback with the additional cash. You'll see the company talk about filing for a listing on a major stock exchange like the Nasdaq. If/when this happens, then that is the time I choose to come in and invest. Make the company prove they can develop the product first, make the company prove they can bring it to market (FDIC approval, clinical trials, etc.), make the company prove their is a demand for their newly developed product, and make the company prove they can form relationships with distributors and can compete with their peers. Don't take a development stage company at face value. Put up or shut up. Once/if they can PROVE these things to you (and you'll know from looking at their books and other filings with the SEC), then they are worthy to have my investment dollars. Only then will the risk become more acceptable. That's just the way I'd play this company. Now let's look at their books. Business "The Genomics field has expanded the number of potential drug targets to several thousand. The CytoGenix proprietary gene down-regulation system is a powerful tool in confirming gene target function. In July 2002, we inaugurated a service geared towards assisting pharmaceutical and biotech companies improve drug discovery efficiency. In addition to our work on in-house targets, we are conducting a pilot studies for several companies. For a fixed fee, we will knockdown a gene in a cell system. This will confirm the gene’s relevance to the disease of interest. Those genes found to be highly disease-related become targets for new drug or molecular therapies. CytoGenix is confident about the Company’s technology’s ability to inhibit these genes. This six to nine month program includes extensive toxicology and efficacy studies in various model animals. The Company is subject to risks common to biopharmaceutical companies, including risks inherent in its research and development efforts and clinical trials, reliance on collaborative partners, enforcement of patent and proprietary rights, the need for future capital, potential competition and uncertainty in obtaining required regulatory approval. In order for a product to be commercialized, it will be necessary for the Company and its collaborators to conduct pre-clinical tests and clinical trials, demonstrate efficacy and safety of the Company’s product candidates, obtain regulatory clearances and enter into distribution and marketing arrangements either directly or through sublicenses. From the Company’s inception through the date of this document, the major role of management has been to obtain sufficient funding for required research, monitoring research progress and developing and licensing intellectual property." For the three months ending June 30 for both 2004 and 2005 we have net losses increasing from $461,935 to $591,514, bringing the total net losses to $20,803,288. The company writes: "The Company’s ability to continue operations through December 31, 2005 depends on its success in obtaining equity financing in an amount sufficient to support its operations through that date. There is substantial doubt that the Company will be able to generate sufficient revenues or be able to raise adequate capital to remain a going concern through December 31, 2005. Based on historical yearly financial requirements, operating capital of approximately $4.1 million will be needed for each of the calendar years 2005 and 2006." So if you already hold this stock, this is the thing to watch. You want to see if the company can raise the $4.1 million needed each calendar year. The company writes: "The process of developing the Company’s products will require significant additional research and development, preclinical testing and clinical trials, as well as regulatory approvals. These activities, together with the Company’s general and administrative expenses, are expected to result in operating losses for at least two more years. The Company will not receive product revenue from therapeutic products unless it completes clinical trials and successfully commercializes or arranges for the commercialization of one or more products, the accomplishment of which no assurance can be given." So you're talking about at least 2 more years of going deeper into debt, and the need to raise an estimated $8.2 million to keep day to day operations going that long. This certainly says that the company is probably too early to invest in. Again, you could lower your risk by waiting for them to complete development on a product or even until one or more of their products make it out of "clinical trials" first. There's plenty of time to invest when the risk/reward ratio tips more in your favor."

LanceJ said: "Looking at their cash flow statement, we have cash at the beginning of the period of $453,235 drop at the end of the reporting period to $123,293. The company writes about this negative cash flow and the possible dilutive effect to existing shareholders as a result: "The Company expects to incur losses for the foreseeable future due to the ongoing activities of the Company to develop new products through research and development and to develop joint ventures and licensing agreements with third parties. The Company expects its existing operations to continue to result in negative cash flow and working capital deficiencies that will require the Company to continue to obtain additional capital. There can be no assurance that the necessary financing will be available to the Company or, if available, that the same will be on terms satisfactory or favorable to it. It is possible that additional equity financing will be highly dilutive to existing shareholders. The Company is currently operating at a loss and expects to continue to depend on cash generated from the sale of debt and equity securities to fund its operating deficit. There can be no assurance that the Company will be able to generate sufficient revenues to meet its operating cash and growth needs or that any equity or debt funding will be available or at terms acceptable to the Company in the future to enable it to continue operating in its current form." Some of these actions for the last period include: On May 9, 2005 the Company issued 136,588 shares of common stock to Peter Imbert for services provided pursuant to the exemption from registration provided by Section 4(2) of the Securities Act of 1933 for transactions not involving a public offering. On May 9, 2005 the Company issued 1,775,002 shares of common stock for an aggregate cash price of $532,500 (or $0.30 per share) in a private placement to accredited investors (Hsiu Lan Chiu -250,000 shares, Ming Tu Chiu– 150,000 shares, Ho Chou Lin – 250,000 shares, Chi Hong Chu – 250,000 shares, Ming Tu Chou– 166,667 shares, Nicholas Wonnell – 75,000 shares, Larry Patrella – 33,334 shares, Noel Jackson– 33,334 shares, Roland Violette – 400,000 shares, Robert Maddox – 100,000 shares, and Kent Wonnell – 66,667 shares) pursuant to the exemption from registration provided by Section 3(b) of the Securities Act of 1933 and Rule 504 thereunder. On June 20, 2005 the Company issued 177,500 shares of common stock to Douglas Nelkin for services provided pursuant to the exemption from registration provided by Section 4(2) of the Securities Act of 1933 for transactions not involving a public offering. Under Investing Activities on the Cash Flow statement, we have an investment in a long term CD line item of $115,500. The company writes: "CytoGenix filed a Declaratory Judgment action in March, 2004, to obtain a finding of nonliability with respect to two license agreements, one for shrimp, and one for horses, originally issued in 1998 to William B. Waldroff. Waldroff and Applied Veterinary Genomics, Inc. (“AVGI”), a party in interest as a sublicensee of Waldroff’s, in Willam B. Waldroff and Applied Veterinary Genomics, Inc. vs. Cytogenix, Inc. counterclaimed for damages, attorneys fees, unrelated torts, and a permanent injunction to honor the purported licenses. A jury trial was held in February, 2005. Both Waldroff and AVGI also sued three directors of CytoGenix for interfering with the licenses. The jury did not assess any damages against any of the directors or against CytoGenix. The court has preliminarily entered a judgment ordering CytoGenix to perform according to the licenses, and for attorneys fees in an amount of $115,500. Pending appeal Cytogenix has established a long-term CD in the amount of $115,500 to comply with the judicial ruling." There is also another legal proceeding: "Phanuel Pursuits, LLC v. CytoGenix, Inc. Phanuel Pursuits, LLC had entered into Option Agreements pursuant to obtaining licenses to commercialize the Company’s anti-herpes product in China and India. Phanuel withdrew from the China option. Phanuel owes unpaid sums due under the remaining Option Agreement, including a specific payment due to purchase the Company’s data they would need for submission to the Indian authorities. Phanuel filed suit October 8, 2004 alleging the Company withheld that data and therefore breached the agreement. The Company believes the suit is completely without merit.""

Slayer said: "Thanks for the info LanceJ. My sister had called me over the weekend telling me that she wanted to invest in CytoGenix. She had spoke to a doctor that had invested in this company and he told her that the topical herpes simplex medication was coming to market and was approved by FDA. The doctor said he had few thousand shares in it and his accountant had bought 400,000 shares of it. Well, this got my sister excited and she knows almost nothing about the market. I know the basics and she wanted me to look in to it. I went to their website and I couldn't find anything about the FDA approving the drug, maybe the doctor and the accountant know something I don't know. On the website it did show the product development timeline and it had CY301 Topical (Herpes Simplex) IND filing 2005. Their financial statements don't look good as of this moment, but if the product hits the market that will quickly change. "Dutton Associates updates its coverage of CytoGenix (OTCBB:CYGX) with its rating maintained at Speculative Buy and a price target of $.90. The 10-page report by Dutton senior analyst William Prather, RPh, MD, is available at [url]www.jmdutton.com[/url] as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. " How reliable are these price targets from the Dutton Associates?"

Slayer said: "Here is a link to the 13 page Dutton Associate Research report. It is a 13 page pdf: [url]http://www.jmdutton.com/research/cygx/reports/cygx_report_040105.pdf[/url]"

Slayer said: "Here is an audio interview with: Malcolm Skolnick, JD, PhD President & CEO CytoGenix, Inc. Dated September 19, 2005 [url]http://www.wallstreetreporter.com/profiles/CytoGenixInc.html[/url]"

LanceJ said: "[QUOTE=Slayer]How reliable are these price targets from the Dutton Associates?[/QUOTE] Not reliable at all. Anyone may enroll a company for research coverage with Dutton Associates, which currently costs US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $47,000.00 from CytoGenix, Inc. for 8 Research Reports with coverage commencing on 07/17/2002. It's just another form of PR that a company can use. The most reliable information is the information I gave you, which came directly from the companies filings with the SEC. Of course the rest is my subjective opinion based on that information. I don't hold any of this companies stock and I wasn't paid anything. I have no alternative agenda. In otherwords, the information that I provided above is a much more realistic picture of the company. Keep in mind I'm not a doctor, and like I said, I don't specialize in "development company" investing. I'm also not a licensed broker, nor should any of my messages be construed as investment advice but rather for entertainment purposes only. I gave you facts, my subjective opinion of those facts, and how, if I were interested in investing in this company at some future point in time (which currently I'm not), how I'd play it to lower the risk associated with investing in a very high risk company like this."